Stateside's Canadian Microcap Board Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Stateside's Canadian Microcap Board

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

downandout

To: PoorOpinion who wrote (1557)	4/5/2016 2:16:31 PM
From: ayeyou	1 Recommendation Read Replies (2) of 1728

Although having cashed in on that bubble feels good I must say I am not resting well not owning a piece of BCT at present. I really like their chances and their medical staff are absolutely top notch people. The business side is a little weak for sure but that can all change with just one decent appointment of a qualified person to take the reins on that front. Word of warning for BCT do NOT appoint a Dr. to this position. They suck at business. :) Put a finance guy/ promoter in their and lets go. BCT keep talking about partners in the news releases so who knows they may have an interested party willing to cover trials cost for first dibs on vaccine. I expect a PP here in the 20 cent area and it is then that I will reload. Who knows I may even get a chunk of that PP. Four month hold wont be a problem here because wheels turn so slowly in the bio med world. BriaCell hopes to begin BriaVax trial this quarter 2016-04-05 08:09 MT - News Release Dr. Saeid Babaei reports BRIACELL TARGETING LAUNCH OF ITS PHASE I/II CLINICAL TRIAL DURING CURRENT QUARTER BriaCell Therapeutics Corp. has provided an update in regard to the planned timing of its phase I/II clinical trial for up to 24 late-stage cancer patients. BriaCell has spent a great deal of time and effort in preparing for the anticipated phase I/II clinical trial. Based upon the company's current discussions with its partners, BriaCell believes it will be in a position to launch the trial within this current quarter. The company is working diligently on a number of key initiatives including completion of its vaccine manufacturing, co-ordinating clinical sites and finalizing its contract research organization (CRO). The company hopes to provide further updates on all fronts in the near future. Dr. Saeid Babaei, chairman of the board, noted: "BriaCell is now in the final stages of preparations for its clinical trial with its lead cancer vaccine, BriaVax. BriaCell is excited about entering the clinic in order to dose patients and hopefully expand upon its phase I results. Additionally, the trial will serve to advance BriaCell's [research and development] platform through utilizing future BriaVax data in complementing its existing gene signature announced last week. We will continue to take steps to work with partners and contractors who can meet our demanding standards and timelines." Manufacturing of the vaccine is nearing completion at the facilities of BriaCell's partner, University of California Davis. As prior noted, UC Davis is manufacturing compliant cGMP-grade (current good manufacturing practice) BriaVax which will be used in dosing patients during the coming trial. The company has already been notified that several BriaVax batches have been completed and hopes to report further on this matter in the coming weeks. Upon receiving U.S. Food and Drug Administration authorization five months ago, BriaCell embarked on identifying a suitable CRO partner in order to facilitate the trial. The company is at the final stages of negotiations and hopes to report further on this within the coming weeks.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next